-
(单词翻译:双击或拖选)
Drug maker1 Eli Lilly and Company said Wednesday it has asked U.S. officials to approve emergency use of an experimental antibody treatment for COVID-19.
Lilly said early results of a study show the treatment reduced hospital emergency room visits for persons with mild or moderate forms of COVID-19. It said the therapy also reduced signs of the disease, the amount of the virus and length of hospital stays for such patients.
The company announced the study's partial results before a meeting with investors2 and the public. The findings have yet to be published or examined by independent scientists.
The antibody treatment appears to work like one given to President Donald Trump3 last Friday. The treatment he took was developed by Regeneron Pharmaceuticals4.
Both therapies are designed to connect human antibodies to the coronavirus that causes COVID-19 and limit its ability to spread. The antibodies are usually given as a one-time treatment through intravenous therapy.
Daniel Skovronsky is a doctor and Eli Lilly's chief scientific officer. He said in a statement, "We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes."
The monotherapy involves an antibody called LY-CoV555. The combination therapy combines that antibody with an antibody called LY-CoV016.
The medical news website StatNews reported that "Lilly had previously5 released results for a similar treatment using one antibody, which experts viewed as promising6. But the new results, of a combination of two antibodies, appear, based on limited data provided in a press release, to be more robust7."
The drug maker is asking the U.S. Food and Drug Administration (FDA) to permit use of its single antibody treatment in emergency situations. The company expects to seek government approval of the combination treatment in November.
At this time, the FDA has only approved the drug remdesivir for emergency use in COVID-19 patients. The president's personal doctor confirmed that Trump has also started a five-day treatment of remdesivir.
Lilly said it has already started manufacturing the drug LY-CoV555. The company expects to have 100,000 doses ready in October and 1 million by the end of the year. It hopes to have 50,000 doses of the combination therapy ready by year's end.
The drug maker added that it is also "working with regulators around the world to make these treatments available."
Words in This Story
intravenous - adj. through a vein8
monotherapy - n. the use of a single drug to treat a disease or condition
outcome - n. something that happens as a result of an activity or process
view - v. to think about something in a particular way
robust - adj. strongly formed
dose - n. the amount of medicine
regulator - n. a government official who controls the public activity by making and enforcing rules
1 maker | |
n.制造者,制造商 | |
参考例句: |
|
|
2 investors | |
n.投资者,出资者( investor的名词复数 ) | |
参考例句: |
|
|
3 trump | |
n.王牌,法宝;v.打出王牌,吹喇叭 | |
参考例句: |
|
|
4 pharmaceuticals | |
n.医药品;药物( pharmaceutical的名词复数 ) | |
参考例句: |
|
|
5 previously | |
adv.以前,先前(地) | |
参考例句: |
|
|
6 promising | |
adj.有希望的,有前途的 | |
参考例句: |
|
|
7 robust | |
adj.强壮的,强健的,粗野的,需要体力的,浓的 | |
参考例句: |
|
|
8 vein | |
n.血管,静脉;叶脉,纹理;情绪;vt.使成脉络 | |
参考例句: |
|
|